about
Salinomycin as a drug for targeting human cancer stem cellsCurrent Stem Cell Biomarkers and Their Functional Mechanisms in Prostate CancerBreast cancer stem-like cells: clinical implications and therapeutic strategiesRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceCancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea AttentionMiRNAs and miRNA Polymorphisms Modify Drug ResponseAldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcomaCancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility StudyGene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.Kinetic Modeling of ABCG2 Transporter Heterogeneity: A Quantitative, Single-Cell Analysis of the Side Population Assay.Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cellsABC transporters in CSCs membranes as a novel target for treating tumor relapse.The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity.Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesisAntitumor efficacy induced by a B16F10 tumor cell vaccine treated with mitoxantrone alone or in combination with reserpine and verapamil in miceBasal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.Estradiol, TGF-β1 and hypoxia promote breast cancer stemness and EMT-mediated breast cancer migrationCancer stem cells and their role in metastasisPathways to breast cancer recurrence.Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.Curcumin enhances the effectiveness of cisplatin by suppressing CD133(+) cancer stem cells in laryngeal carcinoma treatmentRelevance of mortalin to cancer cell stemness and cancer therapy.Drug transport by breast cancer resistance protein.Lung cancer stem cells: tumor biology and clinical implications.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology.Lung cancer stem cells and implications for future therapeutics.Potency of non-steroidal anti-inflammatory drugs in chemotherapy.Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line.ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells.MicroRNA-320a and microRNA-4496 attenuate Helicobacter pylori cytotoxin-associated gene A (CagA)-induced cancer-initiating potential and chemoresistance by targeting β-catenin and ATP-binding cassette, subfamily G, member 2.5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
P2860
Q21285139-E0893A8B-6533-40CD-96AB-FC64F7B4F8F2Q26742062-8DFE482F-5DA3-4546-88D9-2535B1579FE2Q26752170-06E89FBA-120B-47B5-A3F3-692BD4D37F46Q26865927-E34BC3BE-9F83-4D84-9463-E2039DFD96A2Q28069232-5DD5E71A-9D62-4D48-9E77-4BAFBBDFED2EQ28079075-8ECC0353-6710-4A24-BDE9-17ABF119A882Q28482489-BA74EC47-3B2B-48E2-8838-52D912E0A6C5Q28547124-745C04E0-9C63-4F30-A729-7FE8A6E9ED7DQ30828205-4D9703F4-111E-4FE6-A396-739E80AAD1E7Q32186144-6BA539C7-515F-45AF-AC68-3BDCD0DDEE8CQ33772604-9A82417D-0F0F-4D29-8680-9E20602B5ED5Q33879326-5629E271-4561-4485-8510-9BE920DF2AA2Q34105402-B3E735C2-4658-44B8-A109-D7C7190F9F39Q34176588-BA414551-263B-4743-8FF4-E65C2E901510Q34309819-B3B9A8E0-3233-494A-8625-E3B688FBA9D6Q34449025-53559C71-0AD8-492C-ADAF-733824982246Q34459046-7398FFC5-500C-4C94-B1FC-621E743BAAFDQ34615538-F8548F56-2501-4CE0-BA29-52FB98A94B64Q36200232-97B12C65-C7DB-4B32-88AC-D9E13A153BB1Q36230684-50496A89-C6B1-4D53-A37A-F0A1F2FAA71DQ36618624-1F37D404-F620-405A-9197-236FC40DAC06Q36629578-D0CAD8DA-3220-49C8-92C7-64751E92BE8FQ36640378-152DC68E-0AC0-4A46-A389-988C0CDB62FDQ36698757-5CBF6E37-E3D6-48CB-988D-92C028D443BEQ36702139-76BA99E6-7B0F-4635-91D8-9722B2E68E82Q36838947-7E0B2442-D951-4E23-B7CF-6898B3C073B6Q37289139-A0A25190-42CB-4279-83D4-1E324F590FFBQ37625726-7A2F29A3-17AD-4B48-A0B3-C235FA48F359Q37793056-87DD6E33-3ED8-47B7-9302-0D980A37351EQ38035056-5E3DCFAA-F7A5-4754-A78F-9083581CCC94Q38071700-9E9CBB5A-76BE-431C-BEC9-1414F93AFB0BQ38166578-1D67AD26-83A7-4601-88DB-65AFC6A37ADAQ38189297-B8FD1CC7-F4B4-48C5-AADC-9B6528F2B9D4Q38282100-49C818A9-B951-400E-9876-C3871B9186D8Q38292083-22C300EC-B1D3-4D17-B468-23C5892832B9Q38848383-B477A6F9-8F22-4DDF-B4E4-278A7D2E32FEQ39015818-83D558BD-A563-4213-963B-9937C23D81CDQ39061269-EFF7798C-0466-4509-8E3B-6E2BD02A8055Q39069525-6F0D425F-ADD1-4863-8F22-657C9E2C0A5FQ39123460-524DF84B-A5B9-4C96-B4BD-3016918BB72B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ABCG2: the key to chemoresistance in cancer stem cells?
@en
ABCG2: the key to chemoresistance in cancer stem cells?
@nl
type
label
ABCG2: the key to chemoresistance in cancer stem cells?
@en
ABCG2: the key to chemoresistance in cancer stem cells?
@nl
prefLabel
ABCG2: the key to chemoresistance in cancer stem cells?
@en
ABCG2: the key to chemoresistance in cancer stem cells?
@nl
P2860
P1476
ABCG2: the key to chemoresistance in cancer stem cells?
@en
P2093
P2860
P304
P356
10.1517/17425250903228834
P407
P577
2009-12-01T00:00:00Z